Raymond James & Associates’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Raymond James & Associates’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,500	Closed	-$62K	–	4238
2021 Q1	$62K	Buy	+13,500	New	+$314K	﹤0.01%	3834

Raymond James & Associates's GTHX Position: Q3 2024 in Review

Raymond James & Associates sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 797,677 shares — an estimated $1.82M sold.

Raymond James & Associates first reported a position in GTHX in Q4 2019 and held it in 19 quarters. The position peaked at $5.99M in Q3 2022. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

Raymond James & Associates reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Raymond James & Associates sold 797,677 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.82M.
Raymond James & Associates first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2019 and held it in 19 quarters.
Raymond James & Associates's G1 Therapeutics, Inc. Common Stock position peaked at $5.99M in Q3 2022.
0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.